上海，2025年6月18日 - 藥明康德近日宣布，公司提交的溫室氣體減排近期目標已成功通過科學碳目標倡議（SBTi）審核認證。這表明公司溫室氣體減排計劃與全球溫度升高限制在1.5℃以內的目標保持一致，進一步體現了公司踐行可持續發展的堅定承諾。

經SBTi認證，藥明康德承諾以2024年為基準年，到2030年將范圍1和范圍2的溫室氣體絕對排放量減少42%；同時，在相同期限內，將“購買的商品與服務”及“燃料與能源相關活動”中產生的范圍3溫室氣體絕對排放量減少25%（范圍1、2、3是國際公認的溫室氣體排放分類方法）。

SBTi是國際權威機構共同發起的全球性倡議，旨在推動全球企業和金融機構設定科學碳目標，應對氣候變化，避免災難性全球升溫，并助力全球在2050年前實現凈零排放。

“順利通過SBTi認證，是藥明康德在可持續發展道路上的一個重要里程碑?！彼幟骺档侣撓紫瘓绦泄佟SG委員會主席楊青博士表示，“這不僅充分體現了公司科學嚴謹、公開透明地推進溫室氣體減排放，更彰顯了我們積極履行企業社會責任的堅定承諾。藥明康德將持續賦能客戶，推動創新療法早日上市，造福全球患者，與行業同仁攜手構建更健康、更可持續的未來?！?/p>

為了實現上述目標，藥明康德積極落實工藝優化、設備升級、設施改造和技術創新等措施，不斷提升能源使用效率，并逐步通過購買綠電和安裝太陽能光伏發電設施等舉措，提高可再生能源的占比，從而降低自身運營范圍內溫室氣體絕對排放量。此外，公司將與關鍵供應商緊密合作，降低“購買的商品與服務”中產生的溫室氣體絕對排放量，共同推動供應鏈的低碳發展。

作為創新的賦能者、客戶信賴的合作伙伴以及全球健康產業的貢獻者，藥明康德和大多數客戶一樣，積極踐行對可持續發展的承諾，并將其先進的理念戰略性地融入到公司全球運營的方方面面，不斷為社會和環境帶來積極的影響。截至目前，公司已連續四年獲得MSCI ESG 評級“AA”級、入選道瓊斯可持續發展指數（DJSI）；連續三年獲得CDP氣候變化“A-”級領導力評級、Morningstar Sustainalytics ESG“行業最高評級”及“區域最高評級”；首次獲得CDP水安全“A”級領導力評級、EcoVadis企業社會責任評級“金牌”認證。

此外，為深化可持續發展承諾，藥明康德持續拓展全球責任實踐。公司已加入聯合國全球契約組織（UNGC），承諾支持全球契約十項原則。同時，已加入制藥供應鏈倡議（PSCI），成為PSCI供應商合作伙伴。

關于藥明康德

藥明康德（股票代碼：603259.SH/2359.HK）為全球醫藥及生命科學行業提供一體化、端到端的新藥研發和生產服務，在亞洲、歐洲、北美等地均設有運營基地。藥明康德通過獨特的"CRDMO"業務模式，不斷降低研發門檻，助力客戶提升研發效率，為患者帶來更多突破性的治療方案，服務范圍涵蓋化學藥研發和生產、生物學研究、臨床前測試和臨床試驗研究等領域。2024年，藥明康德連續第四年被MSCI評為ESG（環境、社會及管治）AA級。目前，公司的賦能平臺正承載著來自全球30多個國家約6,000家合作伙伴的研發創新項目，致力于將更多新藥、好藥帶給全球病患，早日實現"讓天下沒有難做的藥，難治的病"的愿景。

WuXi AppTec Earns SBTi Validation for Near-Term Emissions Reduction Targets

SHANGHAI, June 17, 2025 - WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, announced that the Science Based Targets initiative (SBTi) has approved WuXi AppTec’s near-term science-based emissions reduction targets. The validation of these targets affirms that the Company’s planned reduction in greenhouse gas (GHG) emissions aligns with the goal of limiting global temperature rise to 1.5°C, underscoring WuXi AppTec’s commitment to meaningful action for a more sustainable future.

With the SBTi validation, WuXi AppTec commits to reducing absolute Scope 1 and 2 GHG emissions by 42% by 2030, based on 2024 levels. The Company also aims to reduce absolute Scope 3 GHG emissions from purchased goods and services and fuel- and energy-related activities by 25% within the same timeframe (Scopes 1, 2, 3 are internationally recognized ways of classifying greenhouse gas emissions).

The SBTi enables companies and financial institutions worldwide to play a pivotal role in combating the climate crisis. It develops standards, tools, and guidance that enable organizations to set GHG emissions reduction targets in line with what is required to keep global heating below catastrophic levels and achieve net-zero by 2050.

“SBTi validation of WuXi AppTec’s near-term targets marks an important milestone in our Company’s sustainability journey,” said Dr. Steve Yang, Co-CEO of WuXi AppTec and Chairman of WuXi AppTec’s ESG Committee. “This recognition underscores our commitment to corporate social responsibility, scientific rigor, and transparency of our greenhouse gas emission reduction efforts. WuXi AppTec is dedicated to supporting our customers in delivering innovative therapies to patients worldwide, working together toward a healthier and more sustainable future.”

To achieve these targets, WuXi AppTec is implementing measures such as process optimization, equipment upgrades, infrastructure renovation, and technological innovations to enhance energy efficiency. The Company is also increasing its use of renewable energy by purchasing green electricity and installing photovoltaic power generation facilities. These efforts aim to progressively reduce carbon emissions within operational boundaries. Furthermore, WuXi AppTec is collaborating with suppliers to reduce absolute GHG emissions associated with purchased goods and services, fostering progress toward a low-carbon supply chain.

As an enabler of innovation, a trusted partner, and a contributor to the global pharmaceutical and life sciences industry, WuXi AppTec strategically integrates sustainability priorities like most of the customers into its global business operations. The Company has received an AA rating in the MSCI ESG ratings for four consecutive years, inclusion in the Dow Jones Sustainability Index (DJSI) for the same duration, and an A- Leadership rating in the CDP Climate Change rating for three consecutive years. WuXi AppTec has also been recognized as an Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics and received an A Leadership rating in the CDP Water Security rating, as well as a Gold Medal in the EcoVadis sustainability rating.

To further its commitment to sustainability, WuXi AppTec has joined the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI) as a supplier partner.

About WuXi AppTec

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec's integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the fourth consecutive year in 2024 and its open-access platform is enabling around 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."

免責聲明：本文僅作信息交流之目的，文中觀點不代表藥明康德立場，亦不代表藥明康德支持或反對文中觀點。本文也不是治療方案推薦。如需獲得治療方案指導，請前往正規醫院就診。

版權說明：歡迎個人轉發至朋友圈，謝絕媒體或機構未經授權以任何形式轉載至其他平臺。轉載授權請在「藥明康德」微信公眾號回復“轉載”，獲取轉載須知。